Krystal Biotech, a gene therapy biotech focused on dermatological diseases, filed on Monday with the SEC to raise up to $35 million in an initial public offering.
The Pittsburgh, PA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol KRYS. Ladenburg Thalmann & Co. is the sole bookrunner on the deal. No pricing terms were disclosed.
